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Marcelo Fridlender, Yoram Kapulnik and Hinanit Koltai*
Institute of Plant Sciences, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel
Plants have had an essential role in the folklore of ancient cultures. In addition to the use
as food and spices, plants have also been utilized as medicines for over 5000 years.
It is estimated that 70–95% of the population in developing countries continues to use
traditional medicines even today. A new trend, that involved the isolation of plant active
compounds begun during the early nineteenth century. This trend led to the discovery
of different active compounds that are derived from plants. In the last decades, more
and more new materials derived from plants have been authorized and subscribed
as medicines, including those with anti-cancer activity. Cancer is among the leading
causes of morbidity and mortality worldwide. The number of new cases is expected
to rise by about 70% over the next two decades. Thus, there is a real need for new
efficient anti-cancer drugs with reduced side effects, and plants are a promising source
for such entities. Here we focus on some plant-derived substances exhibiting anti-
cancer and chemoprevention activity, their mode of action and bioavailability. These
include paclitaxel, curcumin, and cannabinoids. In addition, development and use of
their synthetic analogs, and those of strigolactones, are discussed. Also discussed
are commercial considerations and future prospects for development of plant derived
substances with anti-cancer activity.
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Introduction
Plants have had an essential role in the folklore of ancient cultures. In addition to the use as food
and spices, plants have also been utilized as medicines for over 5000 years. Two remaining living
traditions, the traditional Chinese medicine (TCM) and Ayurveda, the traditional Indian medicine
(TIM) have provided most of the current knowledge related to medicinal plants (Goldman, 2001;
Patwardhan et al., 2005). InTCMandTIM folklore, herbalmedicineswere prepared as teas, tinctures,
poultices, powders, and other types of formulations (Balick and Cox, 1996; Samuelsson, 2004). The
expertise to select the right plants, methods of drug concoction and their specific use has been first
transferred orally from one generation to the next until set down (Kinghorn, 2001; Samuelsson,
2004).
It is estimated that 70–95% of the population in developing countries continues to use traditional
medicines (Robinson and Zhang, 2011). Today medicinal herbs are defined as plants that contain
valuable substanceswith therapeutic or beneficial effect in healing andprevention of various ailments
in man and animals. Herbal products such as plant extracts, dry powders and parts of plants, fungi,
and algae have been used as complementary treatments alongside conventional drugs (Li, 2002;
Robinson and Zhang, 2011).
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A new trend, that involved the isolation of plant active
compounds begun during the early nineteenth century. This
tendency led to the discovery of the analgesic (painkilling) drugs
morphine and codeine from opium (Papaver somniferum L.);
cocaine from Erythroxylum coca; the cardiac glycoside, digitoxin
that was isolated from Digitalis purpurea and Digitalis lanata
that has been used for cardiac conditions and as an anti-cancer
drug, and quinine from Cinchona calisaya Wedd. and Cinchona
succirubra Pav. ex Klotzsch that has antipyretic (fever reducing),
antimalarial, analgesic, and anti-inflammatory properties. Some
of these molecules are still in use (Newman et al., 2000; Kinghorn,
2001; Butler, 2004; Samuelsson, 2004; Balunas and Kinghorn,
2005; Elbaz et al., 2012; Menger et al., 2013). Such natural
compounds provide a huge variety, often with strong biological
activity and therefore play a significant role in the development
of therapeutics treatments (Butler, 2004; Balunas and Kinghorn,
2005; Gordaliza, 2007).
Discovery of plant-derived substances has evolved during the
last 200 years due to the variety of experience and expertise needed
in order to identify such compound. Initially, a plant is identified
by a botanist or ethnobotanist, ethnopharmacologist, or plant
ecologist. Next, plant extracts followed by biological screening
assays are performed by a phytochemist to identify the potential
therapeutic activity followed by isolation of the active compound.
Finally, molecular biology studies are required to reveal the
mode of action and relevant molecular targets. The combination
of these fields determines an interdisciplinary approach termed
pharmacognosy (Kinghorn, 2001; Balunas and Kinghorn, 2005).
Today, it is estimated that about 25–28% of all modern
medicines are directly or indirectly derived from higher plants
demonstrating the enormous medicinal potential of plants that
has been known for thousands of years in traditional medicine
(Samuelsson, 2004; Chin et al., 2006). In the last decades,
more and more new materials derived from plants have been
authorized and subscribed as medicines (Balunas and Kinghorn,
2005; Chin et al., 2006). Several important examples for plant
origin medicines are Arteether (Artemotil®), a sesquiterpene
lactone isolated from Artemisia annua and serves for treatment
of malaria (Van Agtmael et al., 1999; Graul, 2004), Galantamine
(Reminyl®) an amaryllidaceae alkaloid from Galanthus woronowii
used for Alzheimer treatment due to its activity as a selective
acetylcholinesterase inhibitor (Heinrich and Teoh, 2004; Pirttilä
et al., 2004), Apomorphine hydrochloride (Apokyn®) a dopamine
receptor agonist produced in Papaver somniferum L. used to
treat Parkinson’s disease (Deleu et al., 2004), Tiotropium bromide
(Spiriva®) isolated from Atropa belladonna and used for to
treat COPD (chronic obstructive pulmonary disease; Mundy
and Kirkpatrick, 2004; Koumis and Samuel, 2005), Nitisinone
(Orfadin®) a modified mesotrione from Callistemon citrinus
that inhibits the 4-hydroxyphenylpyruvate dioxygenase (HPPD)
enzyme and prevents accumulation of fumaryl and maleyl
acetoacetate in the liver and kidneys (Hall et al., 2001; Mitchell
et al., 2001).
Interestingly, many isolated substances against cancer are
connected with interactions between plants and microbes. Such
interactions are related to rhizospheric or endophytic bacteria,
yeasts, and fungi. These microorganisms penetrate and reside
within plants without injuring them or causing any disease.
Furthermore, such microbes serve as a barrier for colonization
by pathogenic microorganisms and participate in plant growth
and plant defense response by production of a large variety of
secondary metabolites (reviewed in Strobel and Daisy, 2003;
Strobel et al., 2004; Ryan et al., 2008; Chandra, 2012; Kaul
et al., 2012). Since almost all plants co-exist with at least one
endophyte and many molecules have been isolated from such
systems, this review does not aim to summarize this field and it
should review somewhere else. Nonetheless, two recent studies
revealed that extracts from Chaetomium globosum (Wang et al.,
2012; Awad et al., 2014) and 5-Methyl phenazine-1-carboxylic
acid that is produced by Pseudomonas putida (Kennedy et al.,
2015) had cytotoxic effects against cancer cell lines. The similarity
of secondary metabolites produce by endophytes and their hosts
implies on gene transfer between them throughout co-evolution
(Chandra, 2012). Taking advantage of biotechnology new drugs
from endophytes can be manufactured in faster and controlled
processes (Chandra, 2012; Kaul et al., 2012).
In addition to the drugs mentioned above, other plant-derived
substances with anti-cancer activity such as Paclitaxel (Taxol®)
and Camptothecin have been isolated and approved for use.
Here we will focus on some plant-derived substances exhibiting
anti-cancer activity, their mode of action and bioavailability. In
addition, comparison of the use of natural vs. synthetic analogs as
well as commercial consideration will be discussed.
Examples for Plant-Derived Substances
with Anti-Cancer Activity
Cancer is among the leading causes of morbidity and mortality
worldwide. In 2012, 8.2 million cancer related deaths and
approximately 14 million new cases were counted. The number
of new cases is expected to rise by about 70% over the next
two decades. Among men, the five most common sites of cancer
diagnosed in 2012 were lung, prostate, colorectum, stomach, and
liver cancer. Among women the five most common sites diagno-
sed were breast, colorectum, lung, cervix, and stomach cancer.
It is expected that annual cancer cases will rise from 14 million
in 2012 to 22 within the next two decades (http://www.who.
int/mediacentre/factsheets/fs297/en/) and references within).
Today, solid tumors are surgically removed and patients receive
adjuvant radiation treatment and chemotherapy that cause severe
sides effects anddramatically reduce quality of life. In addition, the
toxicity of some treatments restricts their use and effectiveness.
Certain types of cancer such as breast cancer, can be treated using
biological drugs (Herceptin), however the cost of these drugs is
very high and their effectiveness is limited inmost cases to certain
kinds of tumors. In many cases, the tumor develops resistance to a
particular drug and the patient is transferred to a different drug. In
addition, many patients are treated with a combination of several
drugs. More on cancer treatment and survivorship statistics may
be found in DeSantis et al. (2014) and references within. Thus,
there is no doubt that there is a real need for new efficient anti-
cancer drugs with reduced side effects, and plants are a promising
source for such entities. Due to the importance of fighting cancer
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and the variety of potential molecules offered by plants, over 60%
of anti-cancer drugs are directly or indirectly derived from this
kingdom (Gordaliza, 2007).
Probably the most well-known plant-derived anti-cancer drug
is Paclitaxel (Taxol®). The cytotoxic activity of this taxane
dipertene found in extracts from the bark of Taxus brevifoliaNutt.
(Western yew) was first reported by Wani et al. (1971). Later
on, other Taxus species were found to produce this molecule.
Interestingly, In 1993, Taxol was also found to be produced at low
levels by Taxus’ endophytic fungus Taxomyces andreanae (Stierle
et al., 1993) and later on by other endophytic fungi (Guo et al.,
2006) allowing its possible production by future microorganism
fermentation. Taxol’s molecular structure is based on the A, B, and
C rings that harbor two hydroxyl groups, two acetyl groups, one
benzoyl group and an oxetane ring. The side chain A ring together
with the benzoyl group at C2 and the oxetane ring are responsible
for Taxol’s anti-cancer activity. The C3 amide-acyl group in the
C12 chain maintains this activity and the hydroxyl group at C2
enhances it (Kingston, 2000, 2001; Malik et al., 2011).
As other plant-derived compound such as vinca alkaloids,
Taxol disrupts microtubule function. However, in contrast to
vinca alkaloids that disrupt microtubule assembly by binding
depolymerized microtubules, Taxol (essentially all taxanes)
inhibits microtubule disassembly by binding the polymerized
microtubules (Xiao et al., 2006; Hait et al., 2007; Prota et al.,
2013). Microtubules are composed of ab-tubulin heterodimers
and are highly dynamic polymers. Taxol stabilizes this dynamicity
by binding to and altering the conformation of the microtubules.
Taxol was also found to reduce the binding of microtubule-
associated proteins (MAPs). Despite the fact that MAP binding
induces conformational rearrangements of a- and b-tubulin
that promote an overall stabilization of microtubules, Taxol
binding to the MAP-microtubule complex leads to further
stabilization of this complex (Xiao et al., 2012). These disturbances
in microtubule lead to prevention of normal mitotic spindle
formation and function resulting in prevention of mitosis and
thus cell proliferation (Bharadwaj and Yu, 2004; Hait et al.,
2007; Ganguly et al., 2010; Malik et al., 2011; Priyadarshini and
Aparajitha, 2012).
A common problem observed in Taxol-treated patients is
development of drug-resistance over time. However, a combined
treatment of Taxol together with down-regulation of expression
of Bcl-2 (B-cell lymphoma 2), a cell death regulator, or other
apoptotic related genes inhibits invasion, angiogenesis tumor
growth, andmaintains Taxol sensitivity in different types of cancer
cells (George et al., 2009; Yang et al., 2010; Zhou et al., 2010;Maraz
et al., 2011; Sun et al., 2011; Korbakis and Scorilas, 2012; Shajahan
et al., 2012; Morales-Cano et al., 2013).
Although discovered in the early 1970s of the twentieth
century, it took over 25 years to bring Taxol to the market. It was
approved by the Food and Drug Administration (FDA) only in
1992 for the treatment of metastatic ovarian cancer. Clinical trials
also demonstrated encouraging results for other cancer types such
a head, neck, lung, and breast cancer (Suffness, 1995; Gordaliza,
2007). This anti-cancer drug, that is now produced in a semi-
synthetically (see below) process reached the list of the top-selling
20 drugs and sold above $1 billion yearly in 1999 (Kingston, 2000;
Kinghorn, 2001; Malik et al., 2011) with a peak of $1.6 billion in
2000 before generic drugs appeared in the market (Dwivedi et al.,
2010; Buchwald-Werner and Bischoff, 2011). In 2002, sales for
Taxol and Camptothecin, a DNA Topoisomerase I inhibitor, were
more than $2.75 billion, approximately a third of the anti-cancer
drug market. Docetaxel (Taxotere), Taxol’s analog, had sales of
$3 billion in 2009 (Demain and Vaishnav, 2011). Taxol’s success
serves as an example and encouraging story for discovery and
bringing to market additional plant-derived substances.
Chemoprevention represents a different attitude in the battle
against cancer. This approach was defined by (Sporn et al., 1976;
Sharma et al., 2005; Johnson and Mukhtar, 2007) as ingestion
of dietary or pharmaceutical compounds in order to prevent or
delay carcinogenic processes. Many potential chemopreventive
secondary metabolites in both plant extracts as well as purified
molecules isolated from teas, herbs, spices, fruits and vegetables
have been explored (Kelloff et al., 1994; Kinghorn, 2001).
Curcumin (diferuloylmethane) is the most prominent
chemopreventive agent studied. This yellow–orange turmeric
powder, is a polyphenol that accumulates in the rhizome of
Curcuma longa. Both TCM and TIM have used curcumin as
a medicine for treatments of diseases (Aggarwal et al., 2003;
Sharma et al., 2005; Jackson et al., 2013; Thangapazham et al.,
2013). Due to its capabilities to regulated important transcription
factors, cytokines, protein kinases, adhesion molecules and redox
status, curcumin can serve as an anti-inflammatory, anti-oxidant,
anti-proliferative, anti-angiogenic, and antineoplastic agent.
Thus it has been used to treat many different conditions such
as neurodegenerative diseases, cardiovascular diseases, diabetes,
allergy, asthma and bronchitis, inflammatory bowel diseases,
rheumatoid arthritis, renal ischemia, psoriasis, scleroderma,
acquired immunodeficiency disease (AIDS), and cancer as well
as an anti-aging and scar formation agent (Aggarwal et al., 2003;
Anand et al., 2007; Gordaliza, 2007; Johnson and Mukhtar, 2007;
Aggarwal and Harikumar, 2009; Thangapazham et al., 2013).
Hundreds of studies on curcumin anti-cancer activities were
published and are discussed here only briefly. Both in vitro and
in vivo assays have shown inhibition of cell growth in many
types of cancerous cells (Anand et al., 2008; Kunnumakkara
et al., 2008). Maybe one of the most important features related to
curcumin is the suppression of the transcription factor NF-k-B, a
central protein in many types of cancer (Marín et al., 2007). This
inhibition causes reduction in expression of NF-k-B target genes
such as COX-2 and cyclin D1 resulting in apoptosis (Aggarwal
et al., 2003; Thangapazham et al., 2013). Induction of apoptosis
by curcumin was also shown recently when this substance was
given together with the estrogen receptor antagonist Tamoxifen
for treatment of melanoma. Interestingly, also autophagy was
induced using such combination (Cao et al., 2007; Chatterjee and
Pandey, 2011).
Curcumin can act also as chemopreventive agent of
photocarcinogenesis by protecting the skin through diminishing
oxidative stress and suppressing inflammation (Aggarwal et al.,
2003; Heng, 2010). As Taxol, curcumin has also been shown to
affect microtubule assembly leading cells to mitotic arrest (Gupta
et al., 2006). Recently, this type of action by curcumin was found
non-specific only to cancer cells implying its possible impact
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also on normal cells (Jackson et al., 2013). Therefore, additional
studies to assure this plant-derived substance influence on normal
cells and its used in combination with other anti-cancer drugs are
required.
Cannabis sativa has also been used in the TCM, mainly to treat
malaria, constipation, rheumatic pains and during childbirth.
It was only in the nineteenth century that an Irish scientist
and physician, O’Shaughnessy had found that in India it is
used as an analgesic, anticonvulsant, antispasmodic, anti-emetic,
and hypnotic agent. These observations caused its spreading
into Europe and US, until it was outlawed in 1928 and 1937,
respectively due to its negative effects (reviewed in Robson, 2001).
The plant Cannabis sativa is known to contain more than
60 terpenophenolic compounds, named phytocannabinoids
(Mechoulam et al., 2002; Russo and Guy, 2006; Alexander
et al., 2008; Pertwee, 2008). The first active compound isolated
from Cannabis sativa was 9-tetrahydrocannabinol (9-THC),
the active component of marijuana (Gaoni and Mechoulam,
1964). Cannabinoids are mainly used in the last two centuries
as supporting drugs for patients that receive either radiation or
chemotherapies. These drugs ease common symptom and side
effects related to such treatments as nausea, vomiting, cachexia,
and loss of appetite (Robson, 2001; Tramèr et al., 2001; Hall et al.,
2005; Massa et al., 2005; Massa andMonory, 2006; Grotenhermen
and Müller-Vahl, 2012).
Both natural and synthetic cannabinoids act by interactingwith
two specific G-protein-coupled cannabinoid receptors, known
as cannabinoid type 1 receptor (CB1 receptor) and cannabinoid
type 2 receptor (CB2 receptor). The role of CB1 receptors in
regulation of neurotransmitter release and its involvement in
cannabinoid psychoactive effects is well known. In accordance,
these receptors are positioned in central and peripheral nerves
(Massa and Monory, 2006; Matias and Di Marzo, 2006; Howlett
et al., 2010; Pertwee et al., 2010; Smith et al., 2010; Stella,
2010; Turu and Hunyady, 2010). On the hand, the function
of CB2 receptors which are most abundant in the immune
system remained vague for many years although there were
evidences for their participation in regulation of cytokine’s
function and release (Massa and Monory, 2006; Matias and
Di Marzo, 2006). Today there is enough data indicating CB2
role’s in a variety of immunological functional responses mainly
through progression of inflammation events. Participation of CB2
in different signal transduction pathways implies its essential
function in maintenance of a homeostatic immune balance
(Cabral and Griffin-Thomas, 2009; Mukhopadhyay et al., 2010;
Roche and Finn, 2010). In addition, in several different studies,
expression of CB2 at different levels has been also detected in
the central nervous system and brain (Onaivi, 2011). Moreover,
some studies indicate this receptor can be used as a selective
molecular target for therapeutic treatments of both inflammation-
related conditions and neuropathic diseases that display hyper-
inflammation processes (Cabral and Griffin-Thomas, 2009;
Atwood andMackie, 2010; Cencioni et al., 2010; García-Gutiérrez
et al., 2010; Atwood et al., 2012).
The discovery of 9-THC receptors, led to the assumption
that endogenous ligands similar to this molecule should exits.
Indeed, two of these ligands, anandamide and 2-arachidonoyl
glycerol (2-AG), were exposed shortly after. This was followed
by identification of other endogenous ligands as well as synthetic
pathways responsible for both synthesis and degradation of these
cannabinoids (Kogan and Mechoulam, 2006; Massa and Monory,
2006; Cabral and Griffin-Thomas, 2009; Atwood and Mackie,
2010; Pertwee et al., 2010; Stella, 2010; Onaivi, 2011).
The use of cannabinoids as anti-cancer agents is still under
debate due to both cancer promoting and inhibiting effects
shown in the last centuries (Hall et al., 2005; Massa et al., 2005;
Velasco et al., 2015). The fact that cannabinoids play a role in
cell fate decision, proliferation, and apoptosis (Guzmán et al.,
2001) might imply different effects under different conditions
Ligresti et al. (2003) demonstrated that the endocannabinoid
system may play a role in cancer differentiation (by decreasing
the levels of endogenous agonists in differentiated cells vs.
undifferentiated ones), cell growth and cell migration leading
to metastases. On the other hand, their results imply that in
the gastrointestinal system cannabinoid receptors are involved in
inhibition of cell proliferation of colorectal carcinoma (Ligresti
et al., 2003; Massa and Monory, 2006). In studies using cell
lines, the antineoplastic effect of both natural and synthetic
cannabinoids, cannabinoids agonist, and endocannabinoids have
been shown for several cancer types including carcinomas (skin,
lung, prostate, and uterine), neuroblastoma, gliomas, lymphomas,
thyroid epithelioma, and breast cancer. Although the mode of
action leading to these effect is not completely clear, cannabinoids
receptors appear to mediate it (reviewed in Hall et al., 2005;
Oesch and Gertsch, 2009; Sharma et al., 2014; Velasco et al.,
2015). In contrast to these in vitro studies, long-term exposure to
cannabis carcinogens during smoking may lead to cancer in the
aero-digestive tract and lungs (Hall et al., 2005; Aldington et al.,
2008), suggesting that cannabinoids should be administrated with
caution.
Development and Use of Synthetic Analogs
to Plant Derived Substances
One limiting trait related to many plant secondary metabolites
is their poor solubility or poor bioavailability that delays
manufacturing of large amounts required to serve as medicines
(Lipinski et al., 1997). The main solution adopted for different
plant derived substances is the use of semi-synthetic or synthetic
analogs. One known example is morphine that has been
modified (to morphine-6-glucuronide) in order to obtain better
therapeutics features such as side effect (Lötsch and Geisslinger,
2001).
In the case of Taxol, in addition to the low amounts produced
in all Taxus species (Castor and Tyler, 1993; Kingston, 2001; Parc
et al., 2002; Yazdani et al., 2005) this compound is insoluble
in water (Kingston, 2000, 2001). Several different approaches
were explored in attempts to obtained higher amounts of Taxol.
At the end of the twentieth century, two groups reported that
needles of the European Taxus, Taxus baccata L., contain a high
concentration of two Taxol precursors, 10-deacetylbaccatin III
and baccatin (Denis et al., 1988; Guenard et al., 1993). In addition,
plant tissues culture and several semisynthetic approaches were
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tested in order to produce higher amounts of Taxol. Themain step
forwardwas achieved by combining the use of 10-deacetylbaccatin
III and a semisynthetic process for production of the drug. Today,
Taxol and its semisynthetic soluble analog Docetaxel (Taxotere™)
are manufactured in a multi-step semisynthetic process, however
additional improvements are needed in order to reach future
market demands of this important drug (Kingston, 2001; Parc
et al., 2002; Guo et al., 2006; Malik et al., 2011).
Similarly to Taxol, also curcumin is insoluble in water. In
addition, due to reduced absorption in liver and in intestinal
walls and systemic elimination, curcumin has poor bioavailability
(Aggarwal et al., 2003; Sharma et al., 2005) that has been mainly
related to rapid metabolism, fast systemic elimination and poor
absorption (Anand et al., 2007). Therefore, curcumin analogs have
been prepared and their capability to retain therapeutic activities
has been tested. One of the main modifications applied was the
change of the beta-diketone in curcumin to a monocarbonyl
dienone. These analogs demonstrated good bioavailability and
therapeutic effect in rodents (Gordaliza, 2007; Mosley et al.,
2007). At least two other approaches to increase curcumin’s
bioavailability are being explored. The first approach takes
advantage of adjuvants given with curcumin, that will block its
metabolic pathways and/or increase its permeability resulting in
higher blood concentrations and increase in its bioavailability
(Anand et al., 2007; Basnet and Skalko-Basnet, 2011), while the
second technique deals with new formulations of curcumin using
nanoparticles (Anand et al., 2010; Basniwal et al., 2011; Chang
et al., 2013), liposomes (Sun et al., 2010; Dhule et al., 2012),
micelles (Hong et al., 2011; Song et al., 2011; Yang et al., 2012),
and phospholipid complexes (Ghosh et al., 2011; Gupta and Dixit,
2011).
Modifications, formulations and synthetic compounds were
also developed for the Cannabis derived cannabinoid 9-THC
(Kogan and Mechoulam, 2006). One example is cannabidiol
(CBD) another natural cannabinoid from Cannabis sativa and the
major component of Sativex, a drug for multiple sclerosis and
cancer pain. This cannabinoid has low affinity to CB1 and CB2
and therefore has reduced psychotropic effects (McPartland et al.,
2007; Capasso et al., 2008) and it is prescribed in several European
countries. Synthetic capsules of a different drug, Dronabinol,
with 9-tetrahydrocannabinol as its main compound has been
available in the US since 1985, while Nabilone that is a THC
synthetic analog became available in 1983. Today, these drugs
are also available in other countries (Robson, 2001; Tramèr
et al., 2001; Howlett et al., 2010; Grotenhermen and Müller-Vahl,
2012).
Moreover, the endocannabinoid system is highly selective and
has temporal specificity of activation. In the central nerve system
they are not stored in vesicles but release on-demand from
membrane precursors. In non-neuronal organs their expression
is spatial and limited and condition-specific (Massa et al., 2005;
Massa and Monory, 2006). For affecting different organs and
have different activities development of different analogs and
formulation for different conditions might be required.
Strigolactones (SLs) are a new potent group of plant hormones
that might serve as anti-cancer drugs. These plant hormones
were first identified about 50 years ago as germination stimulants
of the parasitic plants Striga and Orobanche (Cook et al., 1966;
reviewed in Xie et al., 2010). This family of terpenoid lactones
is synthesized through the carotenoid synthesis pathway. Their
molecular backbone is built from an ABC ring system that
is connected to a butenolide through an enol ether bridge
(Matusova et al., 2005; Xie et al., 2010). Moreover, SLs act in other
developmental processes across the plants such as suppressors
of outgrowth of pre-formed axillary shoot buds (Gomez-Roldan
et al., 2008; Umehara et al., 2008), and regulators of root
development (Kapulnik et al., 2011; Ruyter-Spira et al., 2011).
Different plants produce different SLs and so far approximately 15
of these hormones have been structurally characterized. Further,
synthetic analogs have been produced in different laboratories
(reviewed by Koltai and Prandi, 2014).
Pollock et al. (2012) were the first to demonstrate the effect of
SLs on cancer cells. Six SLs analogs were shown to inhibit growth
and survival of breast cancer cell lines. All six analogs induced
G2/M arrest but differ in extent of apoptosis. Growth inhibition in
normal cells treated with these analogs was observed only with the
highest SL concentration used, suggesting a dose response to these
molecules. In a subsequent study (Pollock et al., 2014), inhibition
was observed in both solid and non-solid cancer cells such as
colon, lung, prostate, melanoma, osteosarcoma, and leukemic
cell lines. Moreover, SLs were shown to act as new anti-cancer
agents in inhibition of breast cancer in xenograft model with
low toxicity (Mayzlish-Gati et al., 2015). Although the complete
mode of action has not been revealed yet, it was shown that the
tested cancer cells are arrested at G2 through activation of the
p38 and JNK1/2 MAPKs causing stress induction (Pollock et al.,
2012, 2014). In addition, SLs affect the integrity of themicrotubule
network and therefore may inhibit the migratory phenotype of
the highly invasive breast cancer cell lines that were examined
(Mayzlish-Gati et al., 2015).
These results suggest that SLs are potent and promising anti-
cancer agents that induce cell cycle arrest, cellular stress and
apoptosis in cancer cells. Furthermore, the variety of SLs available
in nature from different plants enables development of different
analogs for a large range of cancer treatments and possibly other
pathological conditions and/or personalized treatments.
Commercial Considerations and Future
Prospects
The traditional belief that a single drug, “silver bullet” is
sufficient to treat a single disease has been questioned. This
belief relies on the premise that human diseases have a uniform
underlying genetic basis across patient’s populations. However,
recent advances in genomics demonstrate genetic diversity, i.e.,
polymorphism, implying that different patient populations may
require different tailored drugs to their treatment, as personalized
medicine. Moreover, the shortage in successful new chemical
entities together with a focus of the pharmaceutical industry
on such molecules to serve as “silver bullets” and the shift
of companies from unpredictable research to a more steady
businesses and revenues had created a crisis and loss of faith of
public opinion in “silver bullets.”
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The use of herbal medicines offers a way to alleviate this crisis
in drug development. There are three main advances for herbal
medicine: (1) utilizing the traditional herbal medicine knowledge
may give rise to an inexpensive and more rapid discovery of
new drugs; (2) herbal remedies offer a holistic approach that
complements the disease targeted approach of “Silver bullets”; (3)
synergy between the various components of the herbs which are
an important element of their overall medical effects (Li, 2002).
Themain disadvantage related to herbalmedicines is the lack of
international standardization in terms of methods for evaluating
their composition, efficacy, safety, and quality, consistent
manufacturing practices, regulation and approval processes.
Ironically, vast knowledge and experience in drug development
is available in the pharmaceutical industry. Therefore, combining
the benefits provided by both traditional and modern medicine
has been previously suggested as a promising approach in order
to reveal and bring to market new plant-derived substances.
However, in the last centuries only several herbal medicines
or botanical drugs have been approved by health authorities
for human use (Calixto, 2000; Li, 2002; Liu and Wang, 2008;
Schmidt et al., 2008; Patwardhan and Mashelkar, 2009; Graziose
et al., 2010; Sahoo et al., 2010; Choudhary and Sekhon, 2011;
Newman and Cragg, 2012). Collaboration and coordination
between World Health Organization (WHO), Federal Drug
Administration (FDA), European and other regulatory agencies,
and the pharmaceutical industry worldwide may lead to clear
guidance for development of herbal medications while taking
advantage of the huge potential held by traditional medicine for
development of both anti-cancer and other health promoting
drugs.
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